Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4354307 | 0.92 | FFAR4 (0.46) | LMNAHTTDGAT1HSD11B1MEN1 | |
| SCHEMBL20038408 | 0.84 | LMNA (0.46) | LMNAHTTDGAT1HSD11B1MEN1 | |
| SCHEMBL20249464 | 0.83 | LMNA (0.43) | LMNAHTTDGAT1HSD11B1MEN1 | |
| SCHEMBL1728825 | 0.83 | CKS1B (0.47) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9195108 | 0.81 | PDE10A (0.44) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1728820 | 0.81 | SCD (0.49) | LMNAHTT | |
| SCHEMBL1439618 | 0.80 | LMNA (0.70) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25059012 | 0.80 | SMN1; SMN2 (0.41) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1562375 | 0.79 | MAPT (0.43) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4354310 | 0.79 | MEN1 (0.40) | LMNAHTTDGAT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | LMNA 4393/4885HTT 2476/4885DGAT1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.